Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer - Trial NCT06210971
Access comprehensive clinical trial information for NCT06210971 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hebei Medical University Fourth Hospital and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hebei Medical University Fourth Hospital
Timeline & Enrollment
Phase 2
Feb 01, 2024
Jul 01, 2028
Primary Outcome
Pathologic Complete Response
Summary
This single-arm trial will explore the efficacy and safety of long-course neoadjuvant
 chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients
 with locally advanced rectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06210971
Non-Device Trial